VIRACTA THERAPEUTICS INC (VIRX) Stock Fundamental Analysis

NASDAQ:VIRX • US92765F1084

0.0778 USD
-0.07 (-48.65%)
At close: Feb 3, 2025
0.071 USD
-0.01 (-8.74%)
After Hours: 2/3/2025, 8:01:34 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to VIRX. VIRX was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of VIRX have multiple concerns. VIRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • VIRX had negative earnings in the past year.
  • VIRX had a negative operating cash flow in the past year.
  • In the past 5 years VIRX always reported negative net income.
  • In the past 5 years VIRX always reported negative operating cash flow.
VIRX Yearly Net Income VS EBIT VS OCF VS FCFVIRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -197.14%, VIRX is doing worse than 90.27% of the companies in the same industry.
Industry RankSector Rank
ROA -197.14%
ROE N/A
ROIC N/A
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
VIRX Yearly ROA, ROE, ROICVIRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VIRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIRX Yearly Profit, Operating, Gross MarginsVIRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, VIRX has more shares outstanding
  • The debt/assets ratio for VIRX is higher compared to a year ago.
VIRX Yearly Shares OutstandingVIRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
VIRX Yearly Total Debt VS Total AssetsVIRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • VIRX has an Altman-Z score of -26.24. This is a bad value and indicates that VIRX is not financially healthy and even has some risk of bankruptcy.
  • VIRX has a Altman-Z score of -26.24. This is amonst the worse of the industry: VIRX underperforms 89.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.24
ROIC/WACCN/A
WACCN/A
VIRX Yearly LT Debt VS Equity VS FCFVIRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 0.76 indicates that VIRX may have some problems paying its short term obligations.
  • VIRX has a Current ratio of 0.76. This is amonst the worse of the industry: VIRX underperforms 91.33% of its industry peers.
  • VIRX has a Quick Ratio of 0.76. This is a bad value and indicates that VIRX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • VIRX has a worse Quick ratio (0.76) than 91.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.76
VIRX Yearly Current Assets VS Current LiabilitesVIRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • VIRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.29%, which is quite good.
EPS 1Y (TTM)11.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.15% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.18%
EPS Next 2Y31.22%
EPS Next 3Y19.14%
EPS Next 5Y14.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIRX Yearly Revenue VS EstimatesVIRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2027 2028 2029 2030 2031 50M 100M 150M 200M
VIRX Yearly EPS VS EstimatesVIRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VIRX. In the last year negative earnings were reported.
  • Also next year VIRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIRX Price Earnings VS Forward Price EarningsVIRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIRX Per share dataVIRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VIRX's earnings are expected to grow with 19.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.22%
EPS Next 3Y19.14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VIRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VIRACTA THERAPEUTICS INC

NASDAQ:VIRX (2/3/2025, 8:01:34 PM)

After market: 0.071 -0.01 (-8.74%)

0.0778

-0.07 (-48.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-05
Inst Owners48.83%
Inst Owner Change0.38%
Ins Owners2.41%
Ins Owner Change0%
Market Cap3.09M
Revenue(TTM)N/A
Net Income(TTM)-43.29M
Analysts43.33
Price Target3.06 (3833.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.86%
Min EPS beat(2)-8.04%
Max EPS beat(2)33.76%
EPS beat(4)2
Avg EPS beat(4)12.76%
Min EPS beat(4)-10.69%
Max EPS beat(4)36.03%
EPS beat(8)3
Avg EPS beat(8)8.46%
EPS beat(12)6
Avg EPS beat(12)5.61%
EPS beat(16)8
Avg EPS beat(16)20.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)56.18%
EPS NY rev (1m)0%
EPS NY rev (3m)8.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -197.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.33%
ROA(5y)-80.57%
ROE(3y)-160.27%
ROE(5y)-134.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.76
Altman-Z -26.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y38.18%
EPS Next 2Y31.22%
EPS Next 3Y19.14%
EPS Next 5Y14.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.09%
OCF growth 3YN/A
OCF growth 5YN/A

VIRACTA THERAPEUTICS INC / VIRX FAQ

What is the ChartMill fundamental rating of VIRACTA THERAPEUTICS INC (VIRX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to VIRX.


What is the valuation status for VIRX stock?

ChartMill assigns a valuation rating of 0 / 10 to VIRACTA THERAPEUTICS INC (VIRX). This can be considered as Overvalued.


Can you provide the profitability details for VIRACTA THERAPEUTICS INC?

VIRACTA THERAPEUTICS INC (VIRX) has a profitability rating of 0 / 10.


How financially healthy is VIRACTA THERAPEUTICS INC?

The financial health rating of VIRACTA THERAPEUTICS INC (VIRX) is 0 / 10.